AbbVie agreed to the Trump administration’s most‑favored‑nation (MFN) pricing framework and announced commitments to expand U.S. production capacity, pledging multibillion‑dollar investments. The company said the pact is intended to improve access and reduce list‑price gaps under the administration’s drug‑pricing push. The deal follows a wave of similar agreements by major pharma firms and includes commercial and manufacturing commitments tied to regulatory and policy assurances. Industry observers say MFN pacts will reshape price negotiations and could prompt additional on‑shoring of biologics and drug production.